Table 1 Distribution of 4483 study participants according to selected variables and markers of HCV
Characteristics | Overall | Anti-HCV─ | Anti-HCV+ | Anti-HCV+ and HCV RNA+ | ||
|---|---|---|---|---|---|---|
(n = 4483) | (n = 4147) | (n = 336) | (n = 246) | |||
N (%) | N (%) | N (%) | p-value vs Anti-HCV─ | N (%) | p-value vs Anti-HCV─ | |
Sex | ||||||
Female | 2478 (55.3) | 2304 (55.6) | 174 (51.8) | 128 (52.0) | ||
Male | 2005 (44.7) | 1843 (44.4) | 162 (48.2) | 0.18 | 118 (48.0) | 0.28 |
Age at enrollment (years) | ||||||
< 50 | 2604 (58.1) | 2565 (61.9) | 39 (11.6) | 26 (10.6) | ||
50–59 | 736 (16.4) | 680 (16.4) | 56 (16.7) | 43 (17.5) | ||
60–69 | 552 (12.3) | 455 (11.0) | 97 (28.9) | 73 (29.7) | ||
≥ 70 | 591 (13.2) | 447 (10.8) | 144 (42.9) | < 0.01 | 104 (42.3) | < 0.01 |
Education (years)a | ||||||
< 9 | 2693 (62.0) | 2425 (60.2) | 268 (84.8) | 198 (86.1) | ||
≥ 9 | 1654 (38.0) | 1606 (39.8) | 48 (15.2) | < 0.01 | 32 (13.9) | < 0.01 |
HBV | ||||||
HBsAg─ | 4383 (97.8) | 4052 (97.7) | 331 (98.5) | 241 (98.0) | ||
HBsAg+ | 100 (2.2) | 95 (2.3) | 5 (1.5) | 0.34 | 5 (2.0) | 0.79 |
Fasting plasma glucose (mg/dl)a | ||||||
< 126 | 4148 (93.1) | 3857 (93.6) | 291 (86.9) | 207 (84.5) | ||
≥ 126 | 309 (6.9) | 265 (6.4) | 44 (13.1) | < 0.01 | 38 (15.5) | < 0.01 |
eGFR (ml/min/1.73m2)a | ||||||
< 60 | 203 (4.6) | 165 (4.0) | 38 (11.3) | 26 (10.6) | ||
≥ 60 | 4254 (95.4) | 3957 (96.0) | 297 (88.7) | < 0.01 | 219 (89.4) | < 0.01 |
FIB-4 index scorea | ||||||
< 1.45 | 3540 (79.6) | 3437 (83.6) | 103 (30.7) | 62 (25.2) | ||
1.45–3.25 | 777 (17.5) | 622 (15.1) | 155 (46.3) | 113 (45.9) | ||
> 3.25 | 131 (2.9) | 54 (1.3) | 77 (23.0) | < 0.01 | 71 (29.9) | < 0.01 |
Follow-up (years) | ||||||
Median (IQR) | 12.7 (11.9–13.6) | 12.7 (11.9–13.6) | 12.1 (7.0–13.2) | 11.7 (6.2–13.2) | ||
Total person-years | 52,176.6 | 48,786.8 | 3389.8 | 2375.2 | ||